Susquehanna International Group, LLP Denali Therapeutics Inc. Put Options Transaction History

Susquehanna International Group, LLP

  • $527 Billion
  • Q2 2024

Put Options

5 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 07, 2024
BUY
$15.83 - $23.35 $910,225 - $1.34 Million
57,500 Added 467.48%
69,800 $1.43 Million
Q4 2023

Feb 14, 2024
BUY
$16.2 - $23.18 $199,260 - $285,114
12,300 New
12,300 $263,000
Q2 2023

Aug 11, 2023
SELL
$23.37 - $32.96 $334,191 - $471,328
-14,300 Reduced 52.57%
12,900 $380,000
Q1 2023

May 16, 2023
BUY
$21.91 - $32.67 $595,952 - $888,624
27,200 New
27,200 $626,000
Q3 2022

Nov 14, 2022
SELL
$25.97 - $38.53 $75,313 - $111,737
-2,900 Reduced 27.62%
7,600 $233,000

Others Institutions Holding DNLI

# of Institutions
214
Shares Held
121M
Call Options Held
127K
Put Options Held
38.3K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.85B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email